The case for clinical trial abundance
(ifp.org)
In 2014, the first SGLT2 inhibitor, dapagliflozin, was approved for patients with Type II diabetes for the control of blood glucose levels. Since then, the list of indications for this class of molecules has expanded to include kidney disease (2021) and heart failure (2020) in non-diabetics, both important sources of morbidity and mortality. Despite being an already developed drug with safety data, these repurposings took seven and six years, respectively.
In 2014, the first SGLT2 inhibitor, dapagliflozin, was approved for patients with Type II diabetes for the control of blood glucose levels. Since then, the list of indications for this class of molecules has expanded to include kidney disease (2021) and heart failure (2020) in non-diabetics, both important sources of morbidity and mortality. Despite being an already developed drug with safety data, these repurposings took seven and six years, respectively.